iShares Trust. Holdings as of Jul 31, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency SharesCash or money market | 14.64% | $802.95K | 802,707 |
| Dianthus Therapeutics IncDNTH | 5.34% | $292.85K | 2,739 |
| Xenon Pharmaceuticals IncXENE | 4.87% | $267.22K | 4,264 |
| Praxis Precision Medicines IncPRAX | 4.87% | $267.20K | 868 |
| ACADIA PHARMACEUTICALS INC.ACAD | 4.69% | $257.38K | 9,949 |
| ARROWHEAD PHARMACEUTICALS, INC.ARWR | 4.65% | $255.30K | 3,016 |
| ALKERMES PUBLIC LIMITED COMPANY | 4.60% | $252.45K | 5,153 |
| Scholar Rock Holding CorpSRRK | 4.29% | $235.48K | 4,979 |
| BIOGEN INC.BIIB | 4.18% | $229.13K | 1,129 |
| NEUROCRINE BIOSCIENCES, INC.NBIX | 4.09% | $224.35K | 1,345 |
| argenx SEARGX, Other | 3.86% | $211.75K | 248 |
| PTC THERAPEUTICS, INC.PTCT | 3.85% | $211.44K | 3,109 |
| AXSOME THERAPEUTICS, INC.AXSM | 3.77% | $206.87K | 949 |
| Denali Therapeutics IncDNLI | 3.67% | $201.43K | 8,750 |
| Dyne Therapeutics, IncDYN | 3.56% | $195.50K | 7,764 |
| Edgewise Therapeutics IncEWTX | 3.23% | $177.35K | 4,615 |
| SUPERNUS PHARMACEUTICALS, INC.SUPN | 2.61% | $142.91K | 3,202 |
| AxoGen, Inc.AXGN | 2.34% | $128.36K | 3,041 |
| Biohaven LtdBHVN | 1.82% | $99.59K | 7,377 |
| Idorsia Ltd | 1.44% | $97.68K | 10,423 |
| SAREPTA THERAPEUTICS, INC.SRPT | 1.61% | $88.48K | 5,954 |
| Taysha Gene Therapies IncTSHA | 1.50% | $82.03K | 13,999 |
| Rapport Therapeutics IncRAPP | 1.25% | $68.56K | 1,673 |
| INTEGRA LIFESCIENCES HOLDINGS CORPORATIONIART | 1.19% | $65.18K | 3,915 |
| Neuren Pharmaceuticals Ltd | 1.48% | $57.08K | 6,435 |
| Alto Neuroscience IncANRO | 0.91% | $49.97K | 1,846 |
| LB Pharmaceuticals IncLBRX | 0.89% | $48.94K | 1,221 |
| Medincell SA | 0.75% | $47.57K | 1,372 |
| Annexon IncANNX | 0.78% | $42.70K | 8,380 |
| Solid Biosciences IncSLDB | 0.68% | $37.07K | 4,599 |
| Bright Minds Biosciences IncDRUG | 0.59% | $32.60K | 445 |
| Relmada Therapeutics IncRLMD | 0.52% | $28.76K | 5,416 |
| Design Therapeutics IncDSGN | 0.49% | $26.98K | 2,215 |
| Regenxbio IncRGNX | 0.49% | $26.64K | 2,749 |
| Brainsway LtdBWAY, Other | 0.48% | $26.26K | 1,724 |
| Ceribell IncCBLL | 0.47% | $25.60K | 1,447 |
| NEUROGENE INC.NGNE | 0.44% | $24.34K | 740 |
| Clearpoint Neuro IncCLPT | 0.43% | $23.49K | 1,572 |
| Benitec Biopharma IncBNTC | 0.42% | $23.20K | 1,981 |
| Prothena Corporation PLC | 0.41% | $22.40K | 2,759 |
| OVID THERAPEUTICS INC.OVID | 0.40% | $21.70K | 9,777 |
| Neuropace IncNPCE | 0.36% | $19.89K | 1,543 |
| Newron Pharmaceuticals SpA | 0.28% | $19.00K | 1,060 |
| VANDA PHARMACEUTICALS INC.VNDA | 0.31% | $17.04K | 3,342 |
| Santhera Pharmaceuticals Holding AG | 0.25% | $16.71K | 771 |
| H. LUNDBECK A/S | 1.84% | $15.55K | 15,754 |
| Anavex Life Sciences CorpAVXL | 0.27% | $14.69K | 5,343 |
| Inhibikase Therapeutics IncIKT | 0.23% | $12.38K | 5,679 |
| Capricor Therapeutics IncCAPR | 0.22% | $11.85K | 3,077 |
| Larimar Therapeutics IncLRMR | 0.21% | $11.49K | 3,008 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.